Abemaciclib, Palbociclib or Dalpiciclib Combined with Endocrine Therapy As First-line Treatment in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer
Clinical trial NCT06344780 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06344780
- Sponsor
- Fudan University
- Status
- ACTIVE_NOT_RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2023-05-20
- Primary completion
- 2024-10-01
- Enrollment
- 200
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.